BeiGene (BGNE) said Friday that its antibody drug Tevimbra has received approval from the US Food and Drug Administration for first-line treatment of stomach-esophagus junction cancer.
The approved indication covers a certain type of unresectable or metastatic gastroesophageal junction adenocarcinoma, a rare cancer at the area where the esophagus connects with the stomach, BeiGene said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments